Acurx announces new microbiome data from its phase 2a clinical trial of ibezapolstat for cdi at the 9th international c. diff. conference

Staten island, n.y. , nov. 1, 2021 /prnewswire/ -- acurx pharmaceuticals, inc. (nasdaq: acxp) ("acurx" or the "company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that new microbiome data from its phase 2a clinical trial for c.
ACXP Ratings Summary
ACXP Quant Ranking